CD44v6和PCNA在肾透明细胞癌的表达及其预后价值

CD44v6 and PCNA expression and its prognostic value in clear cell renal cell carcinoma

目的 探讨CD4 4v6和PCNA与肾透明细胞癌 (CCRCC)分级、分期和预后的关系 ,以及两者相互之间的关系。方法 采用免疫组化技术检测 5 8例CCRCC标本中CD4 4v6和PCNA的表达 ,比较两者同Fuhrman分级、病理分期和预后的关系 ,以及两者相互之间的关系。结果 CD4 4v6表达阳性率为 4 4 .8% (2 6 / 5 8) ,为细胞膜染色 ;PCNA表达阳性率为 5 6 .9% (33/ 5 8) ,为细胞核染色。两者表达与分级 (P <0 .0 0 1)和患者生存率 (P <0 .0 1和P <0 .0 5 )均显著相关 ,与病理分期无关 (P >0 .0 5 )。两者相互之间亦无关 (P >0 .0 5 )。结论 CD4 4v6和PCNA表达可能在CCRCC进展中发挥作用 。

Objective To examine the expression of CD44 isoform v6( CD44v6) and proliferating cell nuclear antigen (PCNA) in patients with clear cell renal cell carcinoma (CCRCC) and assess the association of its expression with Fuhrman grade, pTNM stage and prognostic value, as well as their relationship with each other. Methods A retrospective analysis of 58 patients was undertaken. These patients had undergone a radical or partial nephrectomy in our hospital between 1989 and 2000. Immunohistochemical testing was performed by the Envision method using a monoclone mouse antibody (VEF 7 or PC10). Staining characteristics were compared with the clinicopathological results. Results Of the 58 primary tumour specimens, immunohistochemistry showed that 26 tumours (44.8%) expressed CD44v6 which was localized in the cell membrane and 33(56.9%) PCNA in the nucleus. Statistical analysis showed that CD44v6 or PCNA expression was significantly correlated with the Fuhrman grade ( P < 0.001 ) but not with pTNM stage ( P > 0.05 ). There was no correlation between CD44v6 expression and PCNA expression ( P >0.05). The prognosis for CCRCC patients who were CD44v6 or PCNA positive was worse than for patients who were CD44v6 or PCNA negative ( P < 0.01 and 0.05, respectively). Conclusion CD44v6 or PCNA may play a role in the progression of CCRCC, and thus the analysis of CD44v6 or PCNA expression may provide useful prognostic information.